MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Checkpoint Therapeutics Inc

Затворен

СекторЗдравеопазване

4.04 0.25

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.02

Максимум

4.04

Ключови измерители

By Trading Economics

Служители

23

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+31.19% upside

Дивиденти

By Dow Jones

Следващи печалби

9.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

207M

Предишно отваряне

3.79

Предишно затваряне

4.04

Настроения в новините

By Acuity

50%

50%

180 / 386 Класиране в Healthcare

Checkpoint Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.03.2025 г., 10:23 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

Checkpoint Therapeutics Shares Leap Premarket on Takeover by Sun Pharma

14.12.2024 г., 00:24 ч. UTC

Значими двигатели на пазара

Checkpoint Therapeutics' Shares Rise After Securing First FDA Approval

25.07.2024 г., 13:02 ч. UTC

Значими двигатели на пазара

Checkpoint Therapeutics Shares Rise After FDA Accepts Resubmission of Cosibelimab

10.03.2025 г., 02:12 ч. UTC

Придобивния, сливания и поглъщания

Checkpoint Controlling Shareholder Fortress Has Agreed to Vote in Favor of Transaction >524715.BY

10.03.2025 г., 02:12 ч. UTC

Придобивния, сливания и поглъщания

Sun Pharma, Checkpoint Transaction Expected to Complete in 2Q 2025 >524715.BY

10.03.2025 г., 02:11 ч. UTC

Придобивния, сливания и поглъщания

Sun Pharma, Checkpoint, Fortress Biotech Enter Into Royalty Agreement >524715.BY

10.03.2025 г., 02:11 ч. UTC

Придобивния, сливания и поглъщания

Checkpoint Shareholders Entitled to Receive Up to Additional $0.70 if Cosibelimab if Approved in EU Prior to Certain Deadlines >524715.BY

10.03.2025 г., 02:10 ч. UTC

Придобивния, сливания и поглъщания

Checkpoint Shareholders to Receive Upfront Cash Payment of $4.10/Share, Contingent Value Right >524715.BY

10.03.2025 г., 02:10 ч. UTC

Придобивния, сливания и поглъщания

Sun Pharma to Acquire Checkpoint Therapeutics >524715.BY CKPT

10.03.2025 г., 02:06 ч. UTC

Придобивния, сливания и поглъщания

Sun Pharma To Acquire Checkpoint Therapeutics >524715.BY CKPT

Сравнение с други в отрасъла

Ценова промяна

Checkpoint Therapeutics Inc Прогноза

Ценова цел

By TipRanks

31.19% нагоре

12-месечна прогноза

Среден 5.3 USD  31.19%

Висок 7 USD

Нисък 4.1 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Checkpoint Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

1

Купи

2

Задържане

0

Продай

Настроение

By Acuity

180 / 386 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

$

Относно Checkpoint Therapeutics Inc

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with GC Cell. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.